Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 17 studies | 26% ± 9% | |
lung | 13 studies | 25% ± 7% | |
intestine | 8 studies | 25% ± 12% | |
placenta | 5 studies | 25% ± 11% | |
lymph node | 4 studies | 25% ± 14% | |
liver | 4 studies | 27% ± 4% | |
kidney | 3 studies | 27% ± 3% | |
bone marrow | 3 studies | 19% ± 5% | |
uterus | 3 studies | 43% ± 11% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
uterus | 99% | 785.81 | 169 / 170 | 92% | 755.51 | 424 / 459 |
bladder | 100% | 777.52 | 21 / 21 | 88% | 577.16 | 443 / 504 |
lung | 100% | 1581.81 | 576 / 578 | 78% | 298.37 | 903 / 1155 |
breast | 100% | 1000.86 | 457 / 459 | 78% | 491.14 | 869 / 1118 |
intestine | 100% | 1019.73 | 963 / 966 | 72% | 209.54 | 378 / 527 |
esophagus | 89% | 786.98 | 1279 / 1445 | 80% | 321.68 | 147 / 183 |
liver | 99% | 1473.46 | 223 / 226 | 69% | 225.86 | 281 / 406 |
ovary | 77% | 427.61 | 139 / 180 | 90% | 624.36 | 388 / 430 |
thymus | 99% | 975.81 | 644 / 653 | 62% | 198.40 | 378 / 605 |
stomach | 88% | 642.03 | 315 / 359 | 71% | 190.84 | 203 / 286 |
prostate | 99% | 770.95 | 242 / 245 | 51% | 230.75 | 254 / 502 |
kidney | 99% | 2229.62 | 88 / 89 | 48% | 83.71 | 429 / 901 |
brain | 91% | 1230.16 | 2394 / 2642 | 48% | 232.11 | 338 / 705 |
skin | 77% | 514.31 | 1389 / 1809 | 62% | 213.53 | 291 / 472 |
adrenal gland | 93% | 601.28 | 239 / 258 | 46% | 151.09 | 105 / 230 |
pancreas | 45% | 157.06 | 146 / 328 | 81% | 392.71 | 145 / 178 |
lymph node | 0% | 0 | 0 / 0 | 100% | 559.79 | 29 / 29 |
spleen | 100% | 1906.39 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 335.97 | 1 / 1 |
blood vessel | 99% | 1355.81 | 1327 / 1335 | 0% | 0 | 0 / 0 |
adipose | 99% | 1121.46 | 1196 / 1204 | 0% | 0 | 0 / 0 |
heart | 98% | 749.93 | 842 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 96% | 4631.24 | 893 / 929 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 96% | 628.81 | 43 / 45 |
muscle | 54% | 193.70 | 437 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 43% | 153.24 | 34 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0016567 | Biological process | protein ubiquitination |
GO_0045071 | Biological process | negative regulation of viral genome replication |
GO_0032728 | Biological process | positive regulation of interferon-beta production |
GO_0070585 | Biological process | protein localization to mitochondrion |
GO_0032649 | Biological process | regulation of type II interferon production |
GO_0045087 | Biological process | innate immune response |
GO_0009615 | Biological process | response to virus |
GO_0051607 | Biological process | defense response to virus |
GO_0032461 | Biological process | positive regulation of protein oligomerization |
GO_0032733 | Biological process | positive regulation of interleukin-10 production |
GO_0019941 | Biological process | modification-dependent protein catabolic process |
GO_0007229 | Biological process | integrin-mediated signaling pathway |
GO_0045648 | Biological process | positive regulation of erythrocyte differentiation |
GO_0042742 | Biological process | defense response to bacterium |
GO_0032020 | Biological process | ISG15-protein conjugation |
GO_0032729 | Biological process | positive regulation of type II interferon production |
GO_0060339 | Biological process | negative regulation of type I interferon-mediated signaling pathway |
GO_0030501 | Biological process | positive regulation of bone mineralization |
GO_0034340 | Biological process | response to type I interferon |
GO_0031397 | Biological process | negative regulation of protein ubiquitination |
GO_0005576 | Cellular component | extracellular region |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0031386 | Molecular function | protein tag activity |
GO_0031625 | Molecular function | ubiquitin protein ligase binding |
GO_0005178 | Molecular function | integrin binding |
GO_0005515 | Molecular function | protein binding |
Gene name | ISG15 |
Protein name | Ubiquitin-like protein ISG15 (Interferon-induced 15 kDa protein) (Interferon-induced 17 kDa protein) (IP17) (Ubiquitin cross-reactive protein) (hUCRP) ISG15 ubiquitin like modifier |
Synonyms | G1P2 UCRP |
Description | FUNCTION: Ubiquitin-like protein which plays a key role in the innate immune response to viral infection either via its conjugation to a target protein (ISGylation) or via its action as a free or unconjugated protein . ISGylation involves a cascade of enzymatic reactions involving E1, E2, and E3 enzymes which catalyze the conjugation of ISG15 to a lysine residue in the target protein . Its target proteins include IFIT1, MX1/MxA, PPM1B, UBE2L6, UBA7, CHMP5, CHMP2A, CHMP4B and CHMP6. Isgylation of the viral sensor IFIH1/MDA5 promotes IFIH1/MDA5 oligomerization and triggers activation of innate immunity against a range of viruses, including coronaviruses, flaviviruses and picornaviruses . Can also isgylate: EIF2AK2/PKR which results in its activation, RIGI which inhibits its function in antiviral signaling response, EIF4E2 which enhances its cap structure-binding activity and translation-inhibition activity, UBE2N and UBE2E1 which negatively regulates their activity, IRF3 which inhibits its ubiquitination and degradation and FLNB which prevents its ability to interact with the upstream activators of the JNK cascade thereby inhibiting IFNA-induced JNK signaling. Exhibits antiviral activity towards both DNA and RNA viruses, including influenza A, HIV-1 and Ebola virus. Restricts HIV-1 and ebola virus via disruption of viral budding. Inhibits the ubiquitination of HIV-1 Gag and host TSG101 and disrupts their interaction, thereby preventing assembly and release of virions from infected cells. Inhibits Ebola virus budding mediated by the VP40 protein by disrupting ubiquitin ligase activity of NEDD4 and its ability to ubiquitinate VP40. ISGylates influenza A virus NS1 protein which causes a loss of function of the protein and the inhibition of virus replication. The secreted form of ISG15 can: induce natural killer cell proliferation, act as a chemotactic factor for neutrophils and act as a IFN-gamma-inducing cytokine playing an essential role in antimycobacterial immunity. The secreted form acts through the integrin ITGAL/ITGB2 receptor to initiate activation of SRC family tyrosine kinases including LYN, HCK and FGR which leads to secretion of IFNG and IL10; the interaction is mediated by ITGAL . . |
Accessions | ENST00000649529.1 A0A096LNZ9 ENST00000624697.4 ENST00000624652.1 A0A096LPJ4 P05161 |